CEA CAR-T(HuaDao CAR-Tcell)

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug NameCEA CAR-T(HuaDao CAR-Tcell)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CEA
TargetsCarcinoembryonic antigen
Therapy Area/IndicationsNeoplasm MetastasisLiver NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHuadao (Shanghai) Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuadao (Shanghai) Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsColorectal Neoplasms
Inactive IndicationsNeoplasm MetastasisLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A